Enterome Bioscience Raises €10M in Series B Funding

Enterome Bioscience SA, a Paris, France-based developer of innovative disease management solutions based on understanding of the gut microbiome, raised €10m in the first tranche of a Series B funding.

The round was led by existing investors Seventure and Lundbeckfond Ventures, with participation from Omnes Capital.

The company, which has raised a total of €17.5m, intends to use the funds for R&D and business development activities.

Established in 2012 and led by Pierre Belichard, CEO, Enterome is developing novel diagnostic products to support patient stratification, personalized therapies and the clinical development of new drugs for the treatment of microbiome-related diseases such as inflammatory bowel diseases and metabolic diseases (diabetes and obesity).



Join the discussion